Harsh Jogdand

1 ta ish

Bharat Biotech (India)

1. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

   Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand +21

   Maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.717232